Effect of Prognostic Risk Classification on Temsirolimus Efficacy and Safety Outcomes in Patients with Relapsed/Refractory Mantle Cell Lymphoma

被引：0
|
作者：
Hess, Georg [1 ]
Kang, Lisa [2 ]
Moran, Padraig J. [3 ]
机构：
[1] Johannes Gutenberg Univ Mainz, Mainz, Germany
[2] Pfizer Inc, Collegeville, PA USA
[3] Pfizer Inc, Dublin, PA, Ireland
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1165 / 1165
页数：1
相关论文
共 50 条
  • [31] Temsirolimus in Relapsed and/or Refractory Mantle Cell LymphomaProfile Report
    Sheridan M. Hoy
    Kate McKeage
    BioDrugs, 2011, 25 : 193 - 195
  • [32] Clinical Efficacy and Safety in Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Literature Review
    Njue, Annete
    Colosia, Ann
    Trask, Peter C.
    Olivares, Robert
    Khan, Shahnaz
    Abbe, Adeline
    Police, Rachel
    Wang, Jianmin
    Ruiz-Soto, Rodrigo
    Kaye, James A.
    Awan, Farrukh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (01): : 1 - 12
  • [33] Comparison of 2 Doses of Intravenous (IV) Temsirolimus (Temsr) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)
    Jurczak, Wojciech
    Ramanathan, Sundra
    Giri, Pratyush
    Di Raimondo, Francesco
    Mocikova, Heidi
    Clancy, Jill
    Lechuga, Mariajose
    Casey, Michelle
    Boni, Joseph P.
    Giza, Agnieszka
    Hess, Georg
    BLOOD, 2016, 128 (22)
  • [34] Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma
    Tawfiq, Reema K.
    Larson, Melissa C.
    Gile, Jennifer Jane
    Bock, Allison M.
    Poonsombudlert, Kittika
    Maliske, Seth M.
    Maurer, Matthew J.
    Cerhan, James R.
    Kabat, Brian
    Smith, Katherine
    Godby, Richard Curtis
    Paludo, Jonas
    Inwards, David J.
    Ayyappan, Sabarish
    Ansell, Stephen M.
    Habermann, Thomas M.
    Witzig, Thomas E.
    Nowakowski, Grzegorz S.
    Farooq, Umar
    Wang, Yucai
    BLOOD, 2022, 140 : 6489 - 6491
  • [35] Real-World Effectiveness and Safety Outcomes of Acalabrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Patel, Krish
    Teschemaker, Anna
    Tian, Hongping
    Pyrih, Nick
    Kolvenbag, Geert
    Patel, Shweta
    Wahlstrom, Svea K.
    Cui, Lianzhou
    BLOOD, 2024, 144 : 7745 - 7745
  • [36] Treatment Outcomes and Survival Patterns of Asian Patients With Relapsed/Refractory Mantle Cell Lymphoma
    Tan, Jing Yuan
    Qiu, Tian Yu
    Chiang, Jianbang
    Tan, Ya Hwee
    Yang, Valerie Shiwen
    Chang, Esther Wei Yin
    Poon, Eileen
    Somasundaram, Nagavalli
    Farid, Mohamad
    Tao, Miriam
    Lim, Soon Thye
    Chan, Jason Yongsheng
    JOURNAL OF HEMATOLOGY, 2021, 10 (04) : 187 - 195
  • [37] Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial
    Freeman, Ciara L.
    Pararajalingam, Prasath
    Jin, Ling
    Balasubramanian, Sriram
    Jiang, Aixiang
    Xu, Wendan
    Grau, Michael
    Zapukhlyak, Myroslav
    Boyle, Merrill
    Hodkinson, Brendan
    Schaffer, Michael
    Enny, Christopher
    Deshpande, Sanjay
    Sun, Steven
    Vermeulen, Jessica
    Morin, Ryan D.
    Scott, David W.
    Lenz, Georg
    LEUKEMIA, 2022, 36 (10) : 2479 - 2487
  • [38] Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial
    Ciara L. Freeman
    Prasath Pararajalingam
    Ling Jin
    Sriram Balasubramanian
    Aixiang Jiang
    Wendan Xu
    Michael Grau
    Myroslav Zapukhlyak
    Merrill Boyle
    Brendan Hodkinson
    Michael Schaffer
    Christopher Enny
    Sanjay Deshpande
    Steven Sun
    Jessica Vermeulen
    Ryan D. Morin
    David W. Scott
    Georg Lenz
    Leukemia, 2022, 36 : 2479 - 2487
  • [39] Safety and Preliminary Efficacy in Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in TRANSCEND NHL 001
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 10 - 11
  • [40] Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001
    Palomba, Maria Lia
    Gordon, Leo I.
    Siddiqi, Tanya
    Abramson, Jeremy S.
    Kamdar, Manali
    Lunning, Matthew A.
    Maloney, David G.
    Andreadis, Charalambos
    Arnason, Jon E.
    Ghosh, Nilanjan
    Mehta, Amitkumar
    Solomon, Scott R.
    Farazi, Thalia
    Garcia, Jacob
    Dehner, Christine
    Ogasawara, Ken
    Gao, Jie
    Wang, Michael
    BLOOD, 2020, 136
12345